You are here

COPD

Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi, Regeneron flesh out COPD data with Dupixent

Pharmaphorum

Flag link:

Aer Therapeutics Raises $36M for Novel Approach to COPD

Aer Therapeutics Raises $36M for Novel Approach to COPD

BioSpace

Aer Therapeutics

Flag link:

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst

Fierce Pharma

Flag link:

Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD

Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD

Fierce Pharma

clinical trials

Flag link:

AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?

AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?

Fierce Pharma

Flag link:

Sanofi and Regeneron face a high-risk test for Dupixent

Sanofi and Regeneron face a high-risk test for Dupixent

EP Vantage

clinical trials

Flag link:

Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data

Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data

BioSpace

Flag link:

AstraZeneca, C4XD sign exclusive $402 million global license

AstraZeneca, C4XD sign exclusive $402 million global license

Pharmaphorum

drug development

Flag link:

United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease

United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease

Yahoo/Benzinga

United Therapeutics

clinical trials

Flag link:

EpiEndo begins trial of chronic obstructive pulmonary disease treatment

EpiEndo begins trial of chronic obstructive pulmonary disease treatment

Clinical Trials Arena

EpiEndo Pharmaceuticals

Flag link:

On heels of positive COPD readout, Verona to provide new public offering

On heels of positive COPD readout, Verona to provide new public offering

Endpoints

clinical trials

Flag link:

Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026

Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026

BioSpace

Flag link:

Transpire Bio signs with Recipharm for inhaled medicine development

Transpire Bio signs with Recipharm for inhaled medicine development

European Pharmaceutical Review

drug development

Flag link:

AstraZeneca continues to build out its presence in China with new COPD drug manufacturing site

AstraZeneca continues to build out its presence in China with new COPD drug manufacturing site

Endpoints

drug manufacturing

Flag link:

Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program

Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program

Fierce Biotech

Kaleido Biosciences

clinical trials

Flag link:

Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca's Symbicort

Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca's Symbicort

Fierce Pharma

Flag link:

AstraZeneca Purges Two Respiratory Medicines in Big Day for Covis

AstraZeneca Purges Two Respiratory Medicines in Big Day for Covis

BioSpace

Flag link:

Boost for Verona Pharma after trial win with inhaled COPD drug

Boost for Verona Pharma after trial win with inhaled COPD drug

Pharmaforum

clinical trials

Flag link:

Approved! FDA Grants IND Clearance to Three More Candidates Today

Approved! FDA Grants IND Clearance to Three More Candidates Today

BioSpace

frontotemporal dementia

stimulant use disorder

Flag link:

FDA approves Trelegy Ellipta as once-daily single inhaler triple therapy for asthma and COPD

FDA approves Trelegy Ellipta as once-daily single inhaler triple therapy for asthma and COPD

Pharmaceutical Business Review

Trelegy Ellipta

Flag link:

Pages